2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Tuesday, November 15, 2016

9:00AM-11:00AM: Abstract Number: 2977

Treatment of Cryoglobulinemic Vasculitis with Sofosbuvir in Four Combination Protocols

Vasculitis - Poster III: Rarer Vasculitides

9:00AM-11:00AM: Abstract Number: 2694

Treatment of ZAP-70 Mutant SKG Mice with Anti-IL-23 Antibody Alters Fecal Microbiota Composition and Prevents Outgrowth of Bacteria Associated with Susceptibility to Spondyloarthritis and Ileitis

Spondylarthropathies Psoriatic Arthritis – Pathogenesis, Etiology - Poster II

9:00AM-11:00AM: Abstract Number: 2225

Treatment Outcomes of Newly and Formerly Diagnosed Patients with Fibromyalgia after Fibromyalgia Treatment Program

Fibromyalgia, Soft Tissue Disorders, Regional and Specific Clinical Pain Syndromes - Poster II: Clinical Focus

9:00AM-11:00AM: Abstract Number: 2729

Treatment Patterns, Unmet Need, and Impact of Psoriatic Arthritis on Patient-Reported Outcomes in the United States

Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment - Poster III

9:00AM-11:00AM: Abstract Number: 2253

Treatment Persistence with Subcutaneous TNF-Alpha Inhibitors in France

Health Services Research - Poster III

9:00AM-11:00AM: Abstract Number: 2104

Treatment with Tocilizumab Decreases CXCL13 Expression in Cultured Temporal Arteries from Patients with Giant Cell Arteritis

B Cell Biology and Targets in Autoimmune Disease - Poster II: Rheumatoid Arthritis and Other Rheumatic Diseases

9:00AM-11:00AM: Abstract Number: 2645

Treatments for Early Rheumatoid Arthritis (RA): A Systematic Review of Randomized Controlled Trials

Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy - Poster III

9:00AM-11:00AM: Abstract Number: 2433

Trends in Use of Hydroxychloroquine during Pregnancy in SLE Patients from 2001 to 2012

Reproductive Issues in Rheumatic Disorders - Poster

9:00AM-11:00AM: Abstract Number: 2631

Trends and Factors Associated with Use of Biologic Agents As Monotherapy Among US Patients with Rheumatoid Arthritis

Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy - Poster III

9:00AM-11:00AM: Abstract Number: 2303

Trends in Gout and Rheumatoid Arthritis Hospitalizations in Canada from 2000-2011

Metabolic and Crystal Arthropathies - Poster II: Epidemiology and Mechanisms of Disease

9:00AM-11:00AM: Abstract Number: 2331

Trends in Joint Replacement Surgery in Patients with Rheumatoid Arthritis

Orthopedics, Low Back Pain and Rehabilitation - Poster

9:00AM-11:00AM: Abstract Number: 2581

Tripterygium Wilfordii Hook F Applied Topically in Patients with Active Rheumatoid Arthritis

Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy - Poster III

9:00AM-11:00AM: Abstract Number: 2557

Tumor Necrosis Factor (TNF) Sensitizes Rheumatoid Synovial Fibroblasts to TRPA1-Mediated Calcium Flux, Anti-Proliferation and Cell Death

Rheumatoid Arthritis – Human Etiology and Pathogenesis - Poster III

9:00AM-11:00AM: Abstract Number: 2708

Type 17 Immunity in Spondyloarthritis Is Expanded Across Multiple Lymphocyte Subsets

Spondylarthropathies Psoriatic Arthritis – Pathogenesis, Etiology - Poster II

9:00AM-11:00AM: Abstract Number: 2938

U4ATAC Mutation Is Associated with an Immune Dysregulation Syndrome Characterized By Primary Immunodeficiency, Short Stature and Polyglandular Endocrinopathy

T Cell Biology and Targets in Autoimmune Disease - Poster Session II

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].